Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313915 | 0.88 | MAPT (0.55) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL10739901 | 0.88 | MAPT (0.59) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL941245 | 0.88 | IP6K1 (0.74) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL27997684 | 0.87 | PARP1 (0.51) | KDM4EMAPTGAAPTK2BMAPK1 | |
| Hydrochloric Acid SCHEMBL3503462 | 0.86 | MAPT (0.58) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL7673611 | 0.85 | IP6K1 (0.76) | KDM4EMAPTGAAMAPK1HTT | |
| SCHEMBL3224987 | 0.84 | KMT2A (0.52) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL30760533 | 0.84 | KMT2A (0.52) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL2060966 | 0.84 | IP6K1 (0.73) | KDM4EMAPTGAAMAPK1HTT | |
| SCHEMBL24663011 | 0.84 | GAA (0.62) | KDM4EMAPTGAAPTK2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | disclosed |
| US-20220287748-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | REBORNA BIOSCIENCES, INC. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3816160-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | Reborna Biosciences, Inc. (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-3816160-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY | Reborna Biosciences, Inc. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112469707-A | Prophylactic or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2021-03-09 | — | — | CN | disclosed |
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | LIPFORD GRAYSON B | 2010-06-24 | — | — | US | disclosed |
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | LIPFORD GRAYSON B | 2010-06-24 | — | — | US | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070925-A1 | New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070916-A1 | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070925-A1 | New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070916-A1 | 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008030455-A2 | SMALL MOLECULE INHIBITORS OF TOLL-LIKE RECEPTOR 9 | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| CN-1178932-C | Amide derivatives | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1350530-A | Amide derivatives | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | KDM4E 1818/4885MAPT 373/4885GAA 290/4885 |
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | TLR9, TLR3, TLR1 | KDM4E 2032/4885MAPT 3558/4885GAA 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.